Man Group plc Makes New Investment in Vir Biotechnology, Inc. $VIR

Man Group plc bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) during the 2nd quarter, Holdings Channel.com reports. The fund bought 150,688 shares of the company’s stock, valued at approximately $1,536,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Vir Biotechnology by 2,088.4% in the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after buying an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Vir Biotechnology during the 1st quarter worth $359,000. Goldman Sachs Group Inc. raised its holdings in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after acquiring an additional 225,544 shares in the last quarter. Woodline Partners LP raised its holdings in Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after acquiring an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after acquiring an additional 2,566 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Morgan Stanley set a $25.00 price target on Vir Biotechnology in a research note on Thursday, August 6th. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Leerink Partners increased their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Finally, HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.57.

Vir Biotechnology Price Performance

NASDAQ VIR opened at $11.50 on Thursday. The business has a fifty day moving average price of $9.68 and a two-hundred day moving average price of $9.40. The stock has a market capitalization of $1.95 billion, a PE ratio of -6.18 and a beta of 1.63. Vir Biotechnology, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $11.94.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.14. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The company had revenue of $238.95 million for the quarter, compared to analyst estimates of $135.88 million. During the same quarter last year, the company posted ($0.80) EPS. The company’s revenue for the quarter was up 19582.5% compared to the same quarter last year. As a group, sell-side analysts expect that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.